|
|
|
|
LEADER |
04963nam a2200517 4500 |
001 |
978-981-13-7387-9 |
003 |
DE-He213 |
005 |
20191023182346.0 |
007 |
cr nn 008mamaa |
008 |
190527s2019 si | s |||| 0|eng d |
020 |
|
|
|a 9789811373879
|9 978-981-13-7387-9
|
024 |
7 |
|
|a 10.1007/978-981-13-7387-9
|2 doi
|
040 |
|
|
|d GrThAP
|
050 |
|
4 |
|a QH506
|
072 |
|
7 |
|a MBGR
|2 bicssc
|
072 |
|
7 |
|a SCI049000
|2 bisacsh
|
072 |
|
7 |
|a MBGR
|2 thema
|
072 |
|
7 |
|a PSD
|2 thema
|
082 |
0 |
4 |
|a 611.01816
|2 23
|
100 |
1 |
|
|a Cho, Kyung-Hyun.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
245 |
1 |
0 |
|a High-Density Lipoproteins as Biomarkers and Therapeutic Tools
|h [electronic resource] :
|b Volume 1. Impacts of Lifestyle, Diseases, and Environmental Stressors on HDL /
|c by Kyung-Hyun Cho.
|
250 |
|
|
|a 1st ed. 2019.
|
264 |
|
1 |
|a Singapore :
|b Springer Singapore :
|b Imprint: Springer,
|c 2019.
|
300 |
|
|
|a XXIV, 383 p. 244 illus.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
505 |
0 |
|
|a Preface -- Chapter 1. Understanding HDL: overview -- 1-1.HDL and disease -- 1-2.HDL functions and clinical applications -- 1-3.HDL composition : apolipoproteins and enzymes -- 1-4.Maturation of HDL -- 1-5.HDL and blood pressure -- Chapter 2. Change of HDL by life style -- 2-1.Exercise and HDL -- 2-2.Smoking and HDL -- 2-3.Elderly's HDL -- 2-4.HDL depends on body weight -- 2-5.HDL from obese but healthy subject -- 2-6.HDL and apoA-I in smokers' breast milk -- 2-7.Breast milk from frequent trans fatty acid consumers -- 2-8.HDL in cord blood from small neonates -- Chapter 3. Change of HDL in various diseases -- 3-1.HDL from patients with myocardial infarction -- 3-2.HDL from patients with female angina pectoris -- 3-3.HDL and metabolic syndrome -- 3-4.HDL from male patients with atrial fibrillation -- 3-5.HDL from female patients with atrial fibrillation -- 3-6.HDL from patients with hemorrhagic fever with renal syndrome -- 3-7.HDL from patients with rheumatoid arthritis -- 3-8.HDL and prehypertension -- Chapter 4. Detriment of HDL by pollutant and its evaluation -- 4-1.Particulate matter and HDL -- 4-2.Phthalate and HDL -- 4-3.Cadmium and HDL -- 4-4.Humidifier Sterilizer and HDL -- 4-5.Detection of dysfunctional HDL by microfluidics -- 4-6.Evaluation of dysfunctional HDL using zebrafish embryo -- Chapter 5. Change of HDL by food ingredient -- 5-1.Fructose and apoA-I -- 5-2.Fructose and impairment of HDL functionality -- 5-3.Artificial sweeteners and apoA-I -- 5-4.Artificial sweeteners (aspartame, saccharin) and HDL -- 5-5.Aldoketohexoses and HDL -- 5-6.Iron and HDL -- 5-7.Trans fat and HDL -- 5-8.Salt and HDL 576 p -- Summary and perspectives.
|
520 |
|
|
|a This book is the first of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. HDL comprises a diverse group of lipoproteins and its composition and metabolism are dynamic. In this volume, the focus is on the changes observed in HDL under different health statuses, with particular attention to the functional and structural correlations of HDL and apolipoprotein A-1. The impacts of a wide variety of factors on HDL are examined in depth, covering, for example, diet, exercise, smoking, age, diverse diseases, and different forms of environmental pollution. It has long been known that HDL has anti-atherosclerotic and antidiabetic properties, and more recently its anti-aging activities have been recognized. These benefits of HDL are highly dependent on its lipids, proteins, apolipoproteins, and enzymes, and specifically their composition and ratios. In documenting the latest knowledge in this field, this volume will be of interest to both researchers and clinicians.
|
650 |
|
0 |
|a Molecular biology.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
0 |
|a Biomedical engineering.
|
650 |
|
0 |
|a Diabetes.
|
650 |
1 |
4 |
|a Molecular Medicine.
|0 http://scigraph.springernature.com/things/product-market-codes/B1700X
|
650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|0 http://scigraph.springernature.com/things/product-market-codes/B21010
|
650 |
2 |
4 |
|a Biomedical Engineering/Biotechnology.
|0 http://scigraph.springernature.com/things/product-market-codes/B24000
|
650 |
2 |
4 |
|a Diabetes.
|0 http://scigraph.springernature.com/things/product-market-codes/H33045
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811373862
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811373886
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811373893
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-13-7387-9
|z Full Text via HEAL-Link
|
912 |
|
|
|a ZDB-2-SBL
|
950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|